MannKind Corporation (NASDAQ:MNKD) investors have probably had a range of emotions in the past week. The shares price decline sub $0.40 and then witnessed a run above $0.60 on last Thursday, only to note disappointing script figures released.

MannKind is still a speculative play, and as such, traders have the benefit with long time investors suffer change of emotions on rises and dips that are helping few people make money. There is a simple philosophy related to trading. It is always safer to wait to witness a move confirm rather than to jump and be a part of that initial trend.

The highlights

For the week closing October 14, 2016 script sales dropped to nearly 270 from their peak of more than 300 in the preceding week. Again, what seemed promising in one week turned into sheer disappointment in the succeeding week. Until this trend changes, this shares price of MannKind will witness some swings but trade on an overall descending trajectory.

On a QoQ basis, the figures are finally recording some improvement. Around two weeks into 4Q2016 the growth is running 27% better compared to two weeks in 3Q2016. Though that is encouraging, the development remains dull. Sales are well below the mark required to lead equity appreciation. At this phase, true equity rise can only come from resolving the cash condition to get at least 9 months of businesses or a perhaps an inclusive sale of the firm. Either one would halt the bleeding, but neither would enable many shareholders to at least break even.

The YoY comparisons remains a concern in respect of script sales. Sales in 4Q2016 are currently standing 49% below sales in 4Q2015. The saving factor in this entire scenario is the financial features of those sales vary. In 2015, Afrezza was in an association split with Sanofi SA (ADR)(NYSE:SNY). This fiscal MannKind has kept all rights to Afrezza itself.

THE MORNING REPORT

Start your workday the right way with the news that matters most.

Your information is 100% secure with us and will never be shared Disclaimer & Privacy Policy

In terms of forecasts, sales are now starting to decline below even most bearish sales projection. On an aggregate basis, the firm have noted sales of 4,269 scripts since July 1, 2016. The aggregate of lowest projection, as per experts, comes at 4,230.